Adma Biologics (ADMA) Operating Leases (2020 - 2026)

Adma Biologics (ADMA) has 6 years of Operating Leases data on file, last reported at $6.6 million in Q4 2025.

• Quarterly Operating Leases fell 22.37% year-over-year to $6.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.6 million (down 22.37% YoY) and the FY2025 annual result came in at $6.6 million, down 22.37% from the prior year.
• Operating Leases slipped to $6.6 million in Q4 2025, from $9.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $10.9 million in Q2 2022 to a low of $6.6 million in Q4 2025.
• A 5-year average of $9.1 million and a median of $9.3 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases jumped 72.18% — and 2025, when it dropped 22.37%.
• Tracing ADMA's Operating Leases over 5 years: stood at $7.5 million in 2021, then surged by 43.44% to $10.7 million in 2022, then declined by 8.64% to $9.8 million in 2023, then dropped by 12.46% to $8.6 million in 2024, then slipped by 22.37% to $6.6 million in 2025.
• The last three Operating Leases figures came in at $6.6 million (Q4 2025), $9.4 million (Q3 2025), and $9.3 million (Q2 2025), per Business Quant data.